Rethinking enhancement in sport

Annals of the New York Academy of Sciences

Volumn 1093, Issue , 2006, Pages 301-320

  Miah, Andy ^a  

^a UNIVERSITY OF THE WEST OF SCOTLAND   (United Kingdom)

Author keywords

Enhancement; Ethics; Gene doping; Hypoxic training; Sports

Indexed keywords

BODY MODIFICATION; CONCEPT FORMATION; CONCEPTUAL FRAMEWORK; CONFERENCE PAPER; DNA MODIFICATION; DOPING; ETHICS; EXPERT SYSTEM; GENE TRANSFER; HEALTH HAZARD; HYPOXIA; SAFETY; SPORT; TECHNOLOGY; TRAINING; ANOXIA; BLOOD; HUMAN; INTERDISCIPLINARY COMMUNICATION; LEGAL ASPECT; MEDICAL TECHNOLOGY; PHYSIOLOGY; REVIEW;

ANOXIA; BIOMEDICAL ENHANCEMENT; HUMANS; INTERDISCIPLINARY COMMUNICATION; SPORTS;

EID: 33947593811     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1382.020     Document Type: Conference Paper

References (51)

1. AMERICAN ACADEMY OF PEDIATRICS. 2005. Policy statement: use of performance-enhancing substances. Pediatrics 115, 1103-1106.
2. AVENI, A.F. 1976. Man and machine: some neglected considerations on the sociology of sport. Sociology Bulletin 51, 13-23.
3. AUSTRALIA LAW REFORM COMMISSION. 2003. ALRC 96: Essentially Yours. Canberra: Commonwealth of Australia.
4. BARTON-DAVIS, E.R., D.I. SHOTURMA, A. MUSARO, N. ROSENTHAL, and H.L. SWEENEY. 1998. Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proceedings of the National Academy of Sciences, USA 95 (December): 15603-15607.
5. BJERKLIE, D. 1993. High-Tech Olympians. Technology Review 96, 22-30.
6. BOSTROM, N. 2002. Anthropic Bias: Observation Selection Effects in Science and Philosophy. London and New York: Routledge.
7. BRODY, H. 2000. An overview of racket technology. Pp. 43-48 in S.A. Haake and A.O. Coe (eds.), Tennis, Science, Technology. London: Blackwell Science.
8. BRULL, D., S. DHAMRAIT, S. MYERSON, J. ERDMANN, V. REGITZ-ZAGROSEK, M. WORLD, D. PENNELL, S.E. HUMPHRIES, and H. MONTGOMERY. 2001. Bradykinin B2BKR receptor polymorphism and left-ventricular growth response. The Lancet 358, 1155-1156.
9. DENHAM, B.E. 1999a. On drugs in sports in the aftermath of Flo-Jo's death, Big Mac's attack. Journal of Sport and Social Issues 233, 362-367.
10. DENHAM, B.E. 1999b. Building the agenda and adjusting the frame: how the dramatic revelations of Lylle Alzado impacted mainstream press coverage of anabolic steroid use. Sociology of Sport Journal 16, 1-15.
11. DONATI, A. 2005. Criminality in the international doping trade. World Anti-Doping Agency. Hypertext Document. Available Online at: http://www.wada-ama.org.
12. ELLIOTT, C. 2003. Better Than Well: American Medicine Meets the American Dream. New York and London: W.W. Norton & Company.
13. Ethical Issues Review Panel, World Anti-Doping Agency. 2006. Report on Artificially Induced Hypoxic Conditions to Modify Performance. Montreal: World Anti-Doping Agency (Available on request to the organization).
14. FOTHERINGHAM, W. 1996. Sept 6. Cycling: hour of pain, shame or glory. The Guardian. London: 14.
15. FRALEIGH, W.P. 1984. Performance enhancing drugs in sport: the ethical issue. Journal of the Philosophy of Sport XI, 23-29.
16. GARDNER, R. 1989. On performance-enhancing substances and the unfair advantage argument. Journal of the Philosophy of Sport XVI, 59-73.
17. GAYAGAY, G., B. YU, B. HAMBLY, T. BOSTON, A. HAHN, D.S. CELERMAJER, R.J. TRENT. 1998. Elite endurance athletes and the Ace I Allele - the role of genes in athletic performance. Human Genetics 1031, 48-50.
18. GELBERG, J.N. 1995. The Lethal Weapon: how the plastic football helmet transformed the game of football, 1939-1994. Bulletin of Science, Technology, and Society 155-156, 302-309.
19. GOLDSPINK, G. 2001. Gene expression in skeletal muscle. Biochemical Society Transactions 30, 285-290.
20. HOBERMAN, J.M. 1992. Mortal Engines: The Science of Performance and the Dehumanization of Sport. Reprinted 2001, the Blackburn Press. New York: The Free Press.
21. HUMMEL, R.L., and G.S. FOSTER. 1986. A sporting chance: relationships between technological change & concepts of fair play in fishing. Journal of Leisure Research 181, 40-52.
22. INIZAN, F. 1994. Masters and slaves of time. Olympic Review 320, 306-310.
23. KELLY, K. 1994. Out of Control: The New Biology of Machines. London: Fourth Estate.
24. LAMSAM, C., F.H. FU, P.D. ROBBINS, and C.H. EVANS. 1997. Gene therapy in sports medicine. Sports Medicine 252, 73-77.
25. LEVINE, B.D. 2006. Should "artificial" high altitude environments be considered doping? Scandinavian Journal of Medicine and Science in Sports 16(5), 297-301.
26. LIN, J., H. WU, P.T. TARR, C. ZHANG, Z. WU, O. BOSS, L.F. MICHAEL, P. PUIGSERVER, E. ISOTANI, E.N. OLSON, B.B. LOWELL, R. BASSEL-DUBY, and B.M. SPIEGELMANN. 2002. Transcriptional co-activator Pgc-1 drives the formation of slow-twitch muscle fibres. Nature 418, 797-801.
27. MAGDALINSKI, T. 2000. Performance technologies: drugs and fastskin at the Sydney 2000 Olympics. Media International Australia 97(November), 59-69.
28. MARTINEK, V., F.H. FU, et al. 2000. Gene therapy and tissue engineering in sports medicine. The Physician and Sports Medicine 282. Available online at http://www.physsportsmed.com/issues/2000/02 00/huard.htm.
29. MIAH, A. 2000a. Climbing upwards of climbing backwards? The technological metamorphoses of climbing and mountaineering. Chapter 27 in N. Messenger, W. Patterson and D. Brook (eds.), The Science of Climbing and Mountaineering. London: Human Kinetics.
30. MIAH, A. 2000b. The engineered athlete: human rights in the genetic revolution. Culture, Sport, Society 33, 25-40.
31. MIAH, A. 2000c. "New Balls Please": tennis, technology, and the changing game. Pp. 285-292 in S.A. Haake and A.O. Coe. (eds.), Tennis, Science, and Technology. London: Blackwell Science.
32. MIAH, A. 2004. Genetically Modified Athletes: Biomedical Ethics, Gene Doping and Sport. London and New York: Routledge.
33. MIAH, A. 2005a. From anti-doping to a 'performance policy': sport technology, being human, and doing ethics. European Journal of Sport Science 51, 51-57.
34. MIAH, A. 2005b. Doping and the child: an ethical policy for the vulnerable. The Lancet 366, 874-876.
35. MONTGOMERY, H., P. CLARKSON, M. BARNARD, J. BELL, A. BRYNES, C. DOLLERY, J. HAJNAL, H. HEMINGWAY, D. MERCER, P. JARMAN, R. MARSHALL, K. PRASAD, M. RAYSON, N. SAEED, P. TALMUD, L. THOMAS, M. JUBB, M. WORLD, and S. HUMPHRIES. 1999. Angiotensin-converting-enzyme gene insertion/deletion polymorphism and response to physical training. The Lancet 353(13), 541-545.
36. MONTGOMERY, H., R. MARSHALL, H. HEMINGWAY, S. MYERSON, P. CLARKSON, C. DOLLERY, M. HAYWARD, D.E. HOLLIMAN, M. JUBB, M. WORLD, E.L. THOMAS, A.E. BRYNES, N. SAEED, M. BARNARD, J.D. BELL, K. PRASAD, M. RAYSON, P.J. TALMUD, and S.E. HUMPHRIES. 1998. Human gene for physical performance. Nature 39321(May), 221-222.
37. MUNTHE, C. 2000. Selected champions: making winners in an age of genetic technology. Pp. 217-231 in T. Tännsjö and C. Tamburrini (eds.), Values in Sport: Elitism, Nationalism, Gender Equality, and the Scientific Manufacture of Winners. London and New York: E & F.N. Spon.
38. MURRAY, T.H. 1983. The coercive power of drugs in sports. Hastings Center Report August, 24-30.
39. MURRAY, T.H. 1984. Drugs, sports, and ethics. Pp. 107-126 in T.H. Murray, W. Gaylin and R. Macklin (eds.), Feeling Good and Doing Better. Clifton, New Jersey: Humana Press.
40. MURRAY, T.H. 1986a. Guest editorial: drug testing and moral responsibility. The Physician and Sportsmedicine 1411, 47-48.
41. MURRAY, T.H. 1986b. Guest editorial: human growth hormone in sports: no. The Physician and Sportsmedicine 145, 29.
42. PARENS, E., ed. 1998. Enhancing Human Traits: Ethical and Social Implications. Hastings Center Studies in Ethics. Washington, DC: Georgetown University Press.
43. SCIENCE AND TECHNOLOGY SELECT COMMITTEE. 2006, March 1. New Inquiry: Human Enhancement Technologies in Sport. Select Committee for Science and Technology, British Government. Available online at http://www.parliament.uk/ parlimentary_committees/sciences and technology committee/het.cfm (last accessed November 15, 2006).
44. STIVERS, R. 2001. Technology as Magic: The Triumph of the Irrational. New York: Continuum.
45. SVENSSON, E.C., H.B. BLACK, D.L. DUGGER, S.K. TRIPATHY, E. GOLDWASSER, Z. HAO, L. CHU, and J.M. LEIDEN. 1997. Long-termerythropoietin expression in rodents and non-human primates following intramuscular injection of a replication-defective adenoviral vector. Human Gene Therapy 815, 1797-1806.
46. TENNER, E. 1996. Why Things Bite Back: Predicting the Problems of Progress. London: Fourth Estate.
47. THE U.S. PRESIDENT'S COUNCIL ON BIOETHICS. 2002a. Session 4: Enhancement 2: Potential for Genetic Enhancements in Sports. Washington, D.C.: The President's Council on Bioethics. Hypertext Document, available at http://www.bioethics.gov/200207/ session4.html.
48. THE U.S. PRESIDENT'S COUNCIL ON BIOETHICS. 2002b. Sixth Meeting: Session 7: Enhancement 5: Genetic Enhancement of Muscle. Washington, DC: The President's Council on Bioethics. Hypertext Document, available at http://www.bioethics.gov/transcripts/sep02/ session7.html.
49. THE U.S. PRESIDENT'S COUNCIL ON BIOETHICS. 2003. Beyond Therapy: Biotechnology and the Pursuit of Happiness. Washington, DC
50. WORLD ANTI-DOPING AGENCY. 2003. Prohibited Classes of Substances and Prohibited Methods. Montreal: World Anti-Doping Agency.
51. WORLD ANTI-DOPING AGENCY. 2005. The Stockholm Declaration. World Anti-Doping Agency. Hypertext document. Available online at http://www.wada-ama.org (last accessed November 15, 2006).